Posted: December 30, 2025
Jennifer J. Kiblinger, Scientific Director The ASH 2025 meeting offered a mix of innovation and ongoing debates, highlighting exciting developments in hemophilia treatment, anticoagulation strategies, and novel approaches to hemostasis. Some highlights for me: And of course, one of the cutest highlights – the Puppy Playground! Attendees could snuggle and play with puppies during the…
Posted: November 12, 2025
Explore Assays from DiaPharma to Enhance Your Anticoagulation Research FXIa Research Assays from DiaPharma DAPTTIN® TC Reagent* Thrombin Generation Assays* Chromogenic Substrates and Reagents* DOAC-STOP™ Tablets* * For research use only. Not for use in diagnostic procedures. ML-00-01251 Rev 01
Posted: June 27, 2025
See what we unveiled at ISTH 2025! VIEW VIDEO We are grateful for the opportunity to connect and discuss the latest advancements for the hemostasis laboratory at ISTH 2025. The science and collaboration were outstanding. Many thanks to all who worked so hard to make it a success! DiaPharma was proud to highlight: CLINICAL &…
Posted: April 11, 2025
David L. McGlasson, MS, MLS(ASCP) A recent episode of “Differential Discussions” digs into the utility of the chromogenic factor X (CFX) assay for monitoring patients on oral anticoagulant therapy (OAT). Data from previous studies and a case study were discussed. A study was presented that compared International Normalized Ratio (INR) values with CFX results, to…
Posted: December 10, 2024
-Contributed by Abi Kasberg, PhD Immunothrombosis defines the delicate intersection of innate immunity and coagulation. This complex bidirectional interaction between the immune system and clotting components activate each other, leading to abnormal clotting events when unbalanced. A central component to immunothrombosis is the NETosis response of activated neutrophils that result in the expulsion of neutrophil…
Posted: November 13, 2024
David McGlasson The complexities of testing for hemophilia A and B are vast. This Clot Club post serves as an overview of what the laboratory must consider when testing for new EHL products. When comparing different methods used to determine FVIII and FIX activity, the testing laboratory should evaluate the calibrators used, individual kit…
Posted: July 10, 2024
Jennifer J. Kiblinger Scientific Director First, I need to comment how amazing the people of Thailand were. This introvert was a bit worried about going to such a crowded city, but everyone was so hospitable. At the hotel, at the convention center, on the public transit. Those of you who stayed to the end perhaps…
Posted: May 9, 2024
David L. McGlasson, MS, MLS(ASCP) Several years ago, I was the lead author of a manuscript titled: Comparison of six dilute Russell Viper Venom Time (DRVVT) lupus anticoagulant (LA) screen/confirm assay kits.1 The purpose of the protocol was to see if using normalized ratio gave our laboratory any better inter-method consistency when performing the DRVVT…
Posted: December 21, 2023
David L. McGlasson, MS, MLS(ASCP) A few months ago, I posted on LinkedIn that I noticed at recent conferences and journal articles that blood coagulation factors were sometimes referred to in Euro-Arabic numbers (E-A), 0 through 9, instead of Roman numerals.For example, “F8” was written instead of “FVIII”.And sometimes they are used interchangeably. I received…
Posted: October 5, 2023
-Contributed by Abi Kasberg, PhD and Olivia Stricker, PhD Neutrophil extracellular traps (NETs) are an amazing participant of the innate immune system. In a first line of defense, neutrophils expel decondensated chromatin into the extracellular matrix to trap invading pathogens in a mechanism called NETosis. NETs are made up of DNA, histones, and granule…
Posted: September 8, 2023
David L. McGlasson, MS, MLS(ASCP) The most recent ISLH meeting was held in New Orleans, LA May 11-13, 2023. The conference had many State-of-the-Art sessions and I concentrated on the hemostasis/thrombosis presentations. On the first day, Katrien Devreese MD, PhD, Ghent University Hospital, Belgium gave an excellent presentation on the current Diagnosis of Acquired Thrombotic…
Posted: April 14, 2023
David L. McGlasson, MS, MLS(ASCP) At the recent HTRS 2023 Scientific Symposium, a lively discussion in a Plenary Session was presented titled, “Do We Dare to DOAC?” The HTRS session was moderated by Ayesha N. Zia MD, MSCS and Bethany T. Samuelson, MD, and included three presenters: Introduction to Science: Stephan Moll, MD, University of…
Posted: April 13, 2023
Why isn’t this being funded?! Thoughts from HTRS 2023, and a grant opportunity from DiaPharma Jennifer J. Kiblinger Scientific Director The HTRS 2023 Scientific Symposium gave new insights in hemostasis and thrombosis, from health justice initiatives to the latest in antiphospholipid antibody testing. There were lively and insightful debates, even one on how many steel…
Posted: January 25, 2023
David L. McGlasson, MS, MLS(ASCP) Choosing Wisely is a United States-based health educational campaign led by the American Board of Internal Medicine Foundation (ABIMF) and the Consumers’ Union to reduce the prevalence of unnecessary diagnostic tests and treatments.1 The Choosing Wisely campaign goal is to disseminate information for clinicians and patients that provides diagnostic care…
Posted: October 7, 2022
Chicago, IL, August 15-18, 2022 David L. McGlasson, MS, MLS(ASCP) The recent THSNA 2022 meeting that was held in Chicago, IL from August 15-18, 2022, was a welcome event, as attendees for the first time in a couple of years could attend the conference in person or virtually. Finally, attendees had the ability to…
Posted: September 26, 2022
– Contributed by Abi Kasberg, PhD Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare and severe complication of adenoviral-based COVID-19 vaccinations. VITT occurs at a rate of 1:100,000 to 1:1,000,000 and is associated with high morbidity and mortality. Long term complications of VITT and VITT antibodies can persist for more than 9 months and has…
Posted: August 31, 2022
-Contributed by Abi Kasberg, PhD Hereditary Angioedema (HAE) is a rare, inherited, autosomal dominant disorder that is characterized by fluid accumulation and tissue swelling that can be painful and potentially life-threatening. This form of angioedema is driven by vasculature leakage into surrounding tissues including in the hands, feet, lips, genitals, gastrointestinal tract, or airway. Normal…